Joint Biochemical and Genetic Prostate Cancer Risk Stratification
Our study demonstrates the potential of genetic scores to advance screening guidance. The PC risk stratification capabilities of molecular biomarkers in tiered screening strategies merit further study in large cohorts.
Authors
- Teresa L. Johnson‐Pais (ORCID: https://orcid.org/0000-0001-7580-1206)
- Paul C. Boutros (ORCID: https://orcid.org/0000-0003-0553-7520)
- Ian M. Thompson (ORCID: https://orcid.org/0000-0003-0833-952X)
- Jonathan Gelfond (ORCID: https://orcid.org/0000-0002-0773-3683)
- Michael A. Liss (ORCID: https://orcid.org/0000-0001-6978-1026)
- Martin Goros (ORCID: https://orcid.org/0000-0002-1388-9000)
- Tyler M. Seibert (ORCID: https://orcid.org/0000-0002-4089-7399)
- Christine Ibilibor (ORCID: https://orcid.org/0000-0002-3432-7883)
- Robin J. Leach (ORCID: https://orcid.org/0000-0002-3201-5579)
- Nicole Zeltser (ORCID: https://orcid.org/0000-0001-7246-2771)
- Roni Haas
Institutions
- University of San Diego (US)
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Children's Hospital of San Antonio (US)
- Precision for Medicine (United States) (US)
- La Jolla Bioengineering Institute (US)
- University of Colorado Cancer Center (US)
- University of Virginia (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- The Journal of Urology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1097/ju.0000000000004859
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Prostate Cancer Foundation
- Varian Medical Systems
- National Institutes of Health
- University of California, San Diego
- University of Texas Health Science Center at San Antonio
- National Cancer Institute
- Congressionally Directed Medical Research Programs